Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
Kimie Kondo(The University of Texas MD Anderson Cancer Center), Hila Shaim(The University of Texas MD Anderson Cancer Center), Philip A. Thompson(The University of Texas MD Anderson Cancer Center), Jan A. Burger(The University of Texas MD Anderson Cancer Center), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Zeev Estrov(The University of Texas MD Anderson Cancer Center), David Harris(The University of Texas MD Anderson Cancer Center), E Kim(The University of Texas MD Anderson Cancer Center), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), May Daher(The University of Texas MD Anderson Cancer Center), Rafet Başar(The University of Texas MD Anderson Cancer Center), Muharrem Müftüoğlu(The University of Texas MD Anderson Cancer Center), Nobuhiko Imahashi(The University of Texas MD Anderson Cancer Center), Abdullah Alsuliman(The University of Texas MD Anderson Cancer Center), Catherine Sobieski(The University of Texas MD Anderson Cancer Center), Elif Gokdemir(The University of Texas MD Anderson Cancer Center), William G. Wierda(The University of Texas MD Anderson Cancer Center), Nitin Jain(The University of Texas MD Anderson Cancer Center), E Liu(The University of Texas MD Anderson Cancer Center), Elizabeth J. Shpall(The University of Texas MD Anderson Cancer Center), Katayoun Rezvani(The University of Texas MD Anderson Cancer Center)
Cited by 122
Abstract
Related Papers
No related papers found
Powered by citation graph analysis